BiotechTube
Sofie

Sofie

Culver City, United States· Est.
sofie.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $43M

Overview

SOFIE is an integrated radiopharmaceutical company operating across the theranostics value chain, from proprietary R&D to commercial manufacturing and distribution. The company's strategy is built on three pillars: advancing its proprietary pipeline of Fibroblast Activation Protein Inhibitor (FAPI)-based PET imaging agents, providing contract development and manufacturing (CDMO) services through its Theranostics Center of Excellence, and distributing radiopharmaceuticals via a network of 14 radiopharmacies. With its lead candidate, [18F]FAPI-74, in Phase 3 trials for pancreatic and gastroesophageal cancers, SOFIE is positioning itself as a key player in the expanding field of precision oncology and targeted radiotherapy. The company combines service revenue with high-value intellectual property development.

Oncology

Technology Platform

Fibroblast Activation Protein Inhibitor (FAPI)-based radiopharmaceutical platform for diagnostic PET imaging and therapeutic applications (theranostics).

Funding History

2
Total raised:$43M
Series B$33M
Series A$10M

Opportunities

The rapid expansion of the theranostics market creates demand for both novel targeted radiopharmaceuticals and the specialized infrastructure to manufacture and distribute them.
SOFIE's integrated model allows it to capture revenue from services while developing high-value proprietary assets.
Success of its FAPI platform could position it as a leader in a new class of cancer diagnostics and future therapeutics.

Risk Factors

The company faces significant clinical risk as its value is tied to the success of ongoing Phase 3 trials for its lead asset.
The radiopharmaceutical competitive landscape is intensifying, with multiple players targeting FAP.
Furthermore, the complex logistics and regulatory requirements of manufacturing and distributing short-half-life radioactive drugs present ongoing operational and compliance risks.

Competitive Landscape

SOFIE competes in the FAPI tracer space against other biotechs and academic centers, such as those developing gallium-68-based FAPI variants. More broadly, it competes in the radiopharmaceutical CDMO and distribution space with companies like Cardinal Health, Curium, and specialized CMOs. Its integrated model of pipeline, CMO, and network is a key differentiator.

More companies in United States →